Skip to main content

MacroGenics-logo

Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.

{iframe}https://medcitynews.com/2019/02/macrogenics-stock-price-more-than-doubles-on-successful-breast-cancer-study/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=69686183&_hsenc=p2ANqtz-_64lptSEJmSj5heloHSYjN0T5DbGRbmckQwaJSs_K-ecegLV4tkcFzzYz5DiFVBxFceKnUlINN_75UXhHPgp7D651OWw&_hsmi=69686183{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.